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ABSTRACT
Cytochrome P450s CYP1A1 and CYP1A2 can metabolize a broad
range of foreign compounds and drugs. However, these enzymes
have significantly overlapping substrate specificities. To establish
their relative contribution to drug metabolism in vivo, we used
a combination of mice humanized for CYP1A1 and CYP1A2 together
with mice nulled at the Cyp1a1 and Cyp1a2 gene loci. CYP1A2 was
constitutively expressed in the liver, and both proteins were highly
inducible by 2,3,7,8-tetrachlorodibenzodioxin (TCDD) in a number of
tissues, including the liver, lung, kidney, and small intestine. Using
the differential inhibition of the human enzymes by quinidine, we
developed a method to distinguish the relative contribution of
CYP1A1 or CYP1A2 in the metabolism of drugs and foreign com-
pounds. Both enzymes made a significant contribution to the
hepatic metabolism of the probe compounds 7-methoxy and 7-
ehthoxyresorufin in microsomal fractions from animals treated with
TCDD. This enzyme kinetic approach allows modeling of the
CYP1A1, CYP1A2, and non-CYP1A contribution to the metabolism
of any substrate at any substrate, inhibitor, or enzyme concentration
and, as a consequence, can be integrated into a physiologically
based pharmacokinetics model. The validity of the model can then
be tested in humanized mice in vivo.
SIGNIFICANCE STATEMENT
Human CYP1A1 and CYP1A2 are important in defining the efficacy
and toxicity/carcinogenicity of drugs and foreign compounds. In
light of differences in substrate specificity and sensitivity to inhib-
itors, it is of central importance to understand their relative role in
foreign compound metabolism. To address this issue, we have
generated mice humanized or nulled at the Cyp1a gene locus and,
through the use of these mouse lines and selective inhibitors,
developed an enzyme kinetic-basedmodel to enable more accurate
prediction of the fate of new chemicals in humans and which can be
validated in vivo using mice humanized for cytochrome P450–
mediated metabolism.
Introduction
CYP1A2 is a major cytochrome P450 (P450) which accounts for
;12% of the total hepatic P450 content in humans (Iwatsubo et al.,
1997; Achour et al., 2014). CYP1A2 substrates include drugs, industrial
chemicals, and environmental toxicants. The enzyme activity is variable
in humans due to a combination of genetic polymorphism and
environmental factors affecting enzyme expression level and activity.
The expression of both CYP1A1 and CYP1A2 is highly regulated by the
aryl hydrocarbon receptor (AHR). In the case of hepatic CYP1A2, this
can be induced up to 10-fold by AHR ligands (Abraham et al., 2002).
The activated AHR binds to xenobiotic response elements on the 59
flanking region of the CYP1A2 gene. As this element is shared between
CYP1A2 and CYP1A1 genes, many AHR and even some constitutive
androstane receptor ligands simultaneously induce both enzymes
(Corchero et al., 2001; Ueda et al., 2006; Yoshinari et al., 2008,
2010). The active sites of both CYP1A1 and CYP1A2 have a CYP1
family–specific distortion of the F helix in the area of the substrate
binding cavity, causing bending of the helix and resulting in the
formation of an enclosed and planar substrate binding site. This explains
the overlapping substrate and inhibitor specificities for both enzymes
(Sansen et al., 2007; Walsh et al., 2013).
For example, CYP1A1 and CYP1A2 both activate many procarci-
nogens and/or participate in their detoxification (Nebert et al., 2013;
Stiborova et al., 2014). In certain cases, they also mediate the
elimination/metabolic activation of drugs (Lin et al., 2017). As
a consequence, for any studied AHR ligand (potential environmental
toxicant or new pharmaceutical chemical entity), the individual
contribution of both CYP1A1 and CYP1A2 to compound elimination
in humans needs to be estimated using physiologically based pharma-
cokinetic (PBPK) models (Andersen et al., 1997; Santostefano et al.,
1998; Cortessis and Thomas, 2004). Particular attention has to be given
to AHR-mediated induction of the enzymes, as this can markedly affect
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the relative contribution of CYP1A1 and CYP1A2 to metabolism. For
example, 7-ethoxyresorufin O-deethylation (EROD) in untreated rat
liver microsomes is catalyzed by CYP2C6, CYP2B1, CYP2C11, and
CYP3A1/2, whereas the same compound is oxidized predominantly by
CYP1A1 in microsomes from 3-methylcholantrene–treated rats with
CYP1A2 playing a secondary role (Burke et al., 1994). Similarly,
whereas CYP1A2 is considered the sole enzyme catalyzing 7-
methoxyresorufin O-demethylation (MROD) in liver microsomes from
untreated rats (Burke et al., 1994; Floreani et al., 2012), experimental
data suggest CYP1A1 to be a second major enzyme involved in the
reaction in the liver microsomes from safrole- (Burke et al., 1994) or
benzo[a]pyrene-treated animals (Floreani et al., 2012).
Recombinant rat CYP1A1 is ;59 times more active in EROD and
;14 times less active inMROD compared to CYP1A2 (Namkung et al.,
1988), suggesting that 7-ethoxyresorufin (ER) and 7-methoxyresorufin
(MR) are selective substrates for rat CYP1A1 and CYP1A2, respec-
tively. However, recombinant human CYP1A1 is only;2.8 times more
active in EROD and ;5.8 times less active in MROD compared with
human CYP1A2, indicating more extensive overlap in substrate
specificity (Liu et al., 2004). The accuracy of estimates of toxicological
risk or drug pharmacokinetic data generated in rodents compared to
humans is often compromised by the species differences in metabolism
(Cheung and Gonzalez, 2008) and, in a number of cases, differences
between rodent and humanCYP1A1 and CYP1A2 (Turesky et al., 1998;
Turteltaub et al., 1999; Shinkyo et al., 2003). One approach to improving
the predictive power of animal models involves humanization for the
relevant xenobiotic metabolizing enzyme (Cheung andGonzalez, 2008).
Mouse models humanized for CYP1A1 and/or CYP1A2 have demon-
strated human-like procarcinogen activation/detoxification patterns for
2-amino-1-methyl-6-phenyl-imidazola[4,5-b]pyridine (Cheung et al.,
2005) and aristolochic acid I (Levova et al., 2012).
In this study, two new mouse models are described. In one [human
CYP1A1/1A2 (hCYP1A1/1A2)], bothmouseCyp1a1 andCyp1a2were
replaced with the corresponding human orthologs. The second model
(Cyp1a KO) is a Cyp1a1 and Cyp1a2 knockout. The expression of the
Cyp1a/CYP1A enzymes was measured in liver and extrahepatic tissues
of vehicle and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)–treated
animals. A method for the assessment of relative contribution of
CYP1A1 and CYP1A2 to EROD and MROD was developed using
the CYP1A1 selective inhibitor quinidine. The method was applied to
measure individual contributions of human CYP1A1 and CYP1A2 to
EROD and MROD in liver microsomes from TCDD-treated humanized
mice. Values of fraction metabolized by CYP1A2 were determined for
the CYP1A2 substrates tacrine, ramelteon, and caffeine in untreated
humanized and wild-type (WT) animals. The utility of this mouse line
relative to the recently created more-complex P450 humanized model
(Henderson et al., 2019) is discussed.
Materials and Methods
Generation of hCYP1A1/1A2 and Cyp1a KO Mice
hCYP1A1/1A2 andCyp1aKOmicewere generated in a collaboration between
CXR Biosciences (now Concept Life Sciences) and Taconic Biosciences in
a project funded by the Scottish Government through the Intermediate
Technology Institutes (ITI) program (principal investigators C.R.W. and N.S.)
as detailed later. Culture and targeted mutagenesis of embryonic stem cells were
carried out as described previously (Behringer et al., 2014). The murine Cyp1a1
andCyp1a2 gene loci were successively modified by homologous recombination
in C57BL/6NTac mouse embryonic stem cells with two targeting vectors, such
that the genomic sequences between the translational start ATGs and the stop
codons of mouse Cyp1a1 and Cyp1a2 were replaced with the orthologous
genomic sequences of human CYP1A1 and CYP1A2, respectively
(Supplemental Fig. 1), thus removing the murine Cyp1a1 and Cyp1a2 genes.
Southern blot analysis was used to identify correct double-targeted clones,
which were injected into BALB/c blastocysts and transferred into foster
mothers as described previously (Behringer et al., 2014). Chimeric mice were
bred to a germline flipase (Flpe) deleter strain to remove selectable markers
(Supplemental Fig. 1) as described previously (Scheer et al., 2012a).
Heterozygous CYP1A1/1A2 humanized mice were identified by polymerase
chain reaction and either crossed with each other to generate homozygous
hCYP1A1/1A2 mice or crossed to a deleter strain expressing Cre recombinase
to remove the Cyp1a gene locus from the germ line (Supplemental Fig. 1).
Heterozygous Cyp1a knockout offspring were identified by polymerase chain
reaction and further crossed to generate homozygous Cyp1a KO mice. The
Flpe and Cre deleter strains mentioned earlier were generated in house on
a C57BL/6NTac genetic background.
Animal Accommodation and Husbandry
Animal procedures were performed under license from the UK Home Office
[Animal (Scientific Procedures) Act (1986), and 2010/63/EU] and after approval
by the Ethical Review Committee, University of Dundee. Homozygous mice for
each transgenic line were used for experimental studies. C57BL/6NTacmicewere
used as WT controls. Mice were kept in open-top cages with ad libitum access to
food (RM1; Special Diet Services Ltd., Essex, UK) and drinking water, and were
acclimatized for at least 5 days before study commencement. Room temperature
was between 19C and 23C and relative humidity was 40%–70%, with a 12-hour
light/dark cycle (Scheer et al., 2012b).
TCDD Treatment
Mice were given a single intraperitoneal dose of TCDD (10 mg/kg) or vehicle
control (corn oil) and then euthanized 48 hours after the dosing using a rising
concentration of CO2.
TABLE 1
Kinetic parameters of EROD and MROD inhibition by quinidine in microsomes
Microsomes Origin Ks1 6 S.E. Ks2 6 S.E. Ki 6 S.E. a Quinidine Inhibition Type
mM mM mM
EROD
rCYP1A1 0.09 6 0.008 11 6 1 3.3 6 0.35 31 6 8 Mixed
rCYP1A2 (Km) 1.2 6 0.2 NA NA NA NA
Cyp1a KO 0.83 6 0.04 13 6 1.5 422 6 18 NA Noncompetitive
MROD
rCYP1A1 0.47 6 0.07 1.3 6 0.18 2.2 6 0.18 NA Competitive
rCYP1A2 0.58 6 0.08 12 6 3.5 NA NA NA
Cyp1a KO 0.96 6 0.18 3.4 6 0.8 272 6 28 NA Noncompetitive
Ki, dissociation constant of the enzyme-inhibitor complex; Ks1, dissociation constant of the productive enzyme-substrate complex; Ks2, dissociation constant of the
inhibitory enzyme-substrate complex; NA, not applicable; rCYP1A1, recombinant CYP1A1; rCYP1A2, recombinant CYP1A2; a, parameter describing the effect of
inhibitor binding on the binding of the substrate and vice versa.
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Venous blood was removed by cardiac puncture and dispensed into lithium/
heparin-coated tubes. Red blood cells were removed by centrifugation (16.1 krcf
for 10 minutes at room temperature), and the supernatant (plasma) was stored at
approximately 270C.
The gall bladder was removed, and then the liver was removed, weighed, and
scissor-minced in ice-cold KCl [1.15% (w/v)] for subsequent liver subcellular
fractionation. The small intestine and colon were removed and flushed with ice
cold phosphate-buffered saline (PBS) containing a protease inhibitor cocktail
(Roche Diagnostics, Basel, Switzerland).
The duodenum, jejunum, ileum, and colon sections (approximately 10 cm
each) were transferred into separate tubes, flash frozen immediately in liquid
nitrogen, and stored at approximately –70C prior to the preparation of micro-
somes. The heart, lungs, brain, spleen, testis, and kidneys were removed from
each animal, flash frozen in liquid nitrogen, and stored at approximately 270C
prior to microsome preparation.
Preparation of Microsomes
Microsomal fractions were prepared as previously described (Henderson
et al., 2019). In brief, fresh liver samples were homogenized in ice-cold
SET(Sucrose-EDTA-Tris) buffer (0.25 M sucrose, 5 mM EDTA, 20 mM
Tris-HCL, pH 7.4; 9 ml buffer/g liver) and centrifuged at 2000 rpm (Sorvall
RTH-250, 10 minutes, 4C). The supernatant was centrifuged (12,000 rpm,
Sorvall SS-34 rotor, 20 minutes, 4C), the resulting supernatant was
centrifuged (;30,000 rpm, Sorvall TFT-45.6, 90 minutes, 4C) (Thermo-
Fisher Scientific, UK), and microsomal pellets were resuspended in ice-cold
SET buffer and stored at 270C.
Frozen individual duodenum, ileum, jejunum, and colon samples and pooled
(one pool per experimental group) lung, kidney, spleen, heart, brain, and testis
were homogenized in SET buffer containing protease cocktail inhibitor (Roche)
and PMSF (phenylmethylsulfonyl fluoride) (1 mM) using a Polytron homoge-
nizer. Microsomal fractions were prepared as described earlier for liver tissue.
Biochemical Measurements
Clinical Chemistry. The activity of alanine aminotransferase and concentra-
tion of albumin in the plasma samples were measured in the Clinical Pathology
Service Laboratory (Mary Lyon Centre, Harwell, UK).
Total Protein and P450 Determination. Microsomal protein concentration
fractions were measured using a modification of a previously described method
(Lowry et al., 1951) and total hepatic microsomal P450 as previously described
(Omura and Sato, 1964).
Immunoblotting
The expression of Cyp1a, CYP1A1, and CYP1A2 in pooled liver, duodenum,
ileum, jejunum, colon, lung, kidney, spleen, heart, brain, and testis microsomal
samples was determined by immunoblot analysis using primary antibodies
against recombinant rat CYP1A2 (Forrester et al., 1992), human CYP1A1,
and CYP1A2 [AB1258 (Millipore, UK) and PAP 021 (Cypex/Nosan, UK)],
loading 20 mg of microsomal protein per lane. The positive standards were
membrane preparations from bacteria expressing recombinant human CYP1A1
(0.36 pmol) or CYP1A2 (1 pmol). Protein expression was visualized using
Immobilon Western chemiluminescent detection (Millipore) according to
the manufacturer’s instructions, and data were collected and processed
(contrast/brightness adjusted identically for each across the entire image)
using a FujiFilm LAS-3000 mini CCD system and the device software
version 2.2. Acquired images were saved in the tagged image file format
using MultiGauge software (FujiFilm) and transferred to PowerPoint using
Picture Manager (Microsoft Office 2010).
7-Ethoxyresorufin O-Deethylation and 7-Methoxyresorufin O-Demethylation
A mixture of ER (0.93 mM) or MR (0.46 mM) and liver microsomes
(0.004–0.27 mg protein/ml) in 100 mM potassium phosphate buffer (pH 7.4)
supplemented with MgCl2 (3.3 mM) was incubated at 37C for 5 minutes before
the reaction was initiated by injection of NADPH (final concentration, 1.2 mM).
Generation of the fluorescent product was registered in a kinetic mode using
Fluoroscan Ascent FL (excitation filter, 530 nm; emission filter, 584 nm;
Labsystems). Slopes of the linear part of the kinetic curves were calculated using
Ascent Software version 2.4.1 (Labsystems). For each well with the reaction
medium, there was a control well containing the reactionmixture with resorufin (4
pmol). Before addition of NADPH to the reaction wells, fluorescence was
recorded from both the reaction and the control wells. The average fluorescence
was calculated, and the difference between wells with and without resorufin was
used for the conversion of the relative fluorescence units to the picomoles of the
reaction product. Activities in duodenum, ileum, jejunum, colon, lung, kidney,
Fig. 1. Total cytochrome P450 in liver microsomes from vehicle and TCDD-treated
WT, hCYP1A1/1A2, and Cyp1a KO mice. Liver microsomes were prepared from
vehicle (corn oil) and TCDD-treated hCYP1A1/1A2, Cyp1a KO, and WT mice (n5
4), and total cytochrome P450 content was measured as detailed in Materials and
Methods. Data are presented as the mean 6 S.D.; **significantly different from
corresponding corn oil–treated group (unpaired t test; two-tailed P value; P , 0.01).
Fig. 2. Basal and TCDD-inducible expression of Cyp1a/CYP1A in
tissues from WT, Cyp1a KO, and hCYP1A1/1A2 mice. Micro-
somes were prepared from vehicle (corn oil) and TCDD-treated
hCYP1A1/1A2, Cyp1a KO, and WT mice from the tissues shown
and immunoblotted for hCYP1A1 (A and D), human CYP1A2 (B),
and mouse Cyp1a (C) as detailed in Materials and Methods.
Standards: CYP1A1 (0.36 pmol/lane) and CYP1A2 (1 pmol/lane)
expressed in bacterial membranes.
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spleen, heart, brain, and testis microsomes were measured as described earlier
except for the following adjustments: MR concentration was 1mM, concentration
of total microsomal protein in the reaction was in the range of 0.07–0.43 mg/ml,
and amount of resorufin added to calculate the reaction product concentration was
40 pmol.
Inhibition of Recombinant CYP1A1 and CYP1A2 by Quinidine
A mixture of MR (0.57 mM) and microsomes [3.46 pmol/ml CYP1A1 or 10.8
pmol/ml CYP1A2; 0.25 mg protein/ml adjusted using Control Bactosomes
(Cypex)] in phosphate buffer (100 mM KH2PO4, pH 7.4, 3.3 mM MgCl2) was
incubated with quinidine (0–2 mM) in a microtiter plate reader for 5 minutes at
37C prior to the start of the reaction by addition of NADPH (final concentration,
1.2 mM). Generation of fluorescent product was registered in a kinetic mode
(excitation filter, 530 nm; emission filter, 584 nm). Slopes of the linear part of the
kinetic curves were calculated using Ascent Software version 2.4.1 (Labsystems).
Estimation of Individual Contribution of CYP1A1 and CYP1A2 to EROD
and MROD in Liver Microsomes from hCYP1A1/1A2 Mice
A mixture of ER or MR (0.039–5 mM) and microsomes in phosphate buffer
(100 mMKH2PO4, pH 7.4, 3.3 mMMgCl2) was incubated with quinidine [0, 30,
and 200 mM (except for MROD catalyzed by recombinant CYP1A1, where
quinidine was at 0, 6, and 30mM)] in a microtiter plate reader for 5 minutes at 37
C prior to the start of the reaction by addition of NADPH (final concentration, 1.2
mM). Protein enzyme/concentrations were 3.46 pmol/ml for recombinant human
CYP1A1, 10.8 pmol/ml for recombinant human CYP1A2, 0.05mg protein/ml for
liver microsomes from TCDD-treated hCYP1A1/1A2 mice, and 0.25 mg protein/
ml for liver microsomes from TCDD-treated Cyp1 KO mice and vehicle-treated
hCYP1A1/1A2 mice. Where needed, total protein concentration in the reaction
mixtures was adjusted using Control Bactosomes (Cypex), so all reactions
(including those with the recombinant cytochrome P450s) were carried out at
a total protein concentration of 0.25 mg protein/ml. Generation of fluorescent
product was registered in a kinetic mode (excitation filter, 530 nm; emission filter,
584 nm). Slopes of the linear part of the kinetic curves were calculated using
Ascent Software version 2.4.1 (Labsystems). For each well with the reaction
medium, there was a control well containing the reaction mixture with resorufin
(40 pmol). Before addition of NADPH to the reaction wells, fluorescence was
recorded both from the reaction and from the control wells. The average
fluorescence was calculated, and the difference between wells with and without
resorufin was used for the conversion of the relative fluorescence units to the
picomoles of the reaction product. The selected quinidine concentrations provided
marked CYP1A1 inhibition, which is essential for precise calculation of inhibition
constants (Kakkar et al., 2000) while leaving sufficient enzyme activity for
accurate measurement. Kinetic parameters of quinidine inhibition of recombinant
CYP1A1 are presented in Table 1.
Microsomal Stability of Ramelteon and Tacrine
A 880-ml mixture of ramelteon (1.25 mM) and C57BL6J (WT), Cyp1a KO,
hCYP1A1/1A2, or pooled human liver microsomes (0.625 mg protein/ml) in
phosphate buffer (100 mM KH2PO4, pH 7.4, 3.3 mM MgCl2) was incubated for
5 minutes at 37C in a water bath before an 80-ml aliquot was mixed with 100 ml
of ice-cold methanol containing tacrine (100 ng/ml) as an internal standard,
followed by addition of 20ml of NADPH solution (6mM) in the phosphate buffer.
The reaction was started by addition of 200 ml of NADPH to the remaining
mixture of ramelteon with microsomes, and 100-ml aliquots were taken at 1, 2, 5,
10, 15, 20, and 30 minutes after the reaction start; mixed with an equal volume of
ice-cold methanol containing the internal standard; incubated on ice for at least
20 minutes; and centrifuged for 15 minutes at 16,000 rcf and14C on Centrifuge
5415 R (Eppendorf, Hamburg, Germany). Control incubations were carried out
without the cofactor or microsomes. The concentration of ramelteon in the
supernatant was measured by high-performance liquid chromatography–tandem
mass spectrometry (MS/MS). Chromatographic separation was performed on
a Prodigy Phenyl-3 column (5mm, 50 2.0mm; Phenomenex) using an injection
volume of 10 ml and a run time of 7 minutes. Mobile phase consisted of
0.1% solutions of formic acid inwater (solvent A) and acetonitrile (solvent B). For
Fig. 3. EROD and MROD activities in hepatic and extrahepatic tissues from WT, Cyp1a KO, and hCYP1A1/1A2 mice. Liver microsomes were prepared from vehicle (corn
oil) and TCDD-treated hCYP1A1/1A2, Cyp1a KO, and WT mice for the tissues shown, and EROD (A) and MROD (B) activities were measured as detailed in Materials and
Methods. Microsomes from extrahepatic tissues of TCDD-treated hCYP1A1/1A2 and WT mice were prepared, and EROD (C) and MROD (D) activities were measured.
Data are presented as the mean 6 S.D. (n 5 4); *significantly different from corresponding WT group (unpaired t test; two-tailed P value; **P , 0.01; ***P , 0.001;
****P , 0.0001). Heart, lung, spleen, kidney, brain, and testis microsomes were prepared from pooled organs of each experimental group. Their activities are presented as
the mean 6 S.D. of three measurements of the pooled sample. No test for statistical significance was performed on these data. HLM, pooled human liver microsomes.
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elution, a linear gradient from 20% to 60% of solvent B in 4 minutes was used,
followed by 3-minute equilibration at 20% B. The multiple reaction monitoring
parameters for ramelteon and tacrine were 260.28, 199.2 (precursor ion) and
204.21, 171.11 (product ion), respectively. The concentrations of ramelteon were
calculated from the calibration curve. Tacrine microsomal stability was measured
as described for ramelteon except that the final microsomal protein concentration
was 1 mg/ml; the reaction aliquots were collected at 5, 10, 20, 30, 40, 50, and
60 minutes after the reaction start; and the reaction was stopped by mixing with
120ml of 167 mMhydrochloric acid containing 183 ng/ml caffeine as the internal
standard. The mobile phase gradient started at 5% B. The multiple reaction
monitoring parameters for tacrine and caffeine were 199.2, 195.18 (precursor ion)
and 171.11, 138.07 (product ion), respectively.
Caffeine Pharmacokinetics
Caffeine [5 mg/kg; 10 ml/kg; dissolved in 50 mM sodium citrate buffer (pH
4.7)] was delivered toWT, Cyp1a KO, and hCYP1A1/1A2mice (four animals per
experimental group) by oral administration. A separate experimental group
consisted of mice with conditionally deleted hepatic P450 oxidoreductase
(Henderson et al., 2003) [hepatic reductase null (HRN) mice]. Whole blood
samples from WT and hCYP1A1/1A2 mice were collected at 12, 24, and
40 minutes and 1, 2, 3, 4, 6, and 8 hours after the administration. Whole blood
samples from HRN and Cyp1a1/1a2 KO mice were collected at 12, 24, and
40 minutes and 1, 3, 6, 8, 12, and 24 hours postadministration. The collected
whole blood samples (10 ml) were mixed with an equal volume of heparin
solution in water (15 U/ml), frozen in liquid nitrogen, and stored at 270C. The
Fig. 4. Effect of quinidine on MROD activity catalyzed by recombinant human
CYP1A1 and CYP1A2. Recombinant human CYP1A1 (closed circles) and
CYP1A2 (open circles) were coexpressed with human P450 reductase in bacterial
microsomes, and activity was measured as detailed in Materials and Methods.
Fig. 5. Effect of quinidine on EROD and MROD activities catalyzed by recombinant human CYP1A1, CYP1A2, and liver microsomes from Cyp1a KO mice at different
substrate concentrations. EROD (A, C, and E) and MROD (B, D, and F) catalyzed by recombinant human CYP1A1 (A and B), CYP1A2 (C and D), and liver microsomes
from TCDD-treated Cyp1a KO mice (E and F) at different concentrations of substrate and quinidine, as detailed in Materials and Methods. Symbols are the measured
reaction rates. Lines are nonlinear regression analysis of the data using eqs. 1–6 (for details, see Data Analysis in the Supplemental Materials).
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concentration of caffeine in whole blood was measured by liquid
chromatography–MS/MS. Calibration standards were prepared by spiking whole
mouse blood with an appropriate amount of caffeine standard and mixing the
whole blood aliquots with an equal volume of heparin solution in water (15 U/ml).
The test samples and calibration standards (20 ml) were mixed with 80 ml of
perchloric acid (1.5%) containing tacrine (50 ng/ml) as internal standard,
vortexed, and centrifuged at 16,100 rcf for 15 minutes. The supernatant was
collected, and the centrifugation step was repeated. The supernatant was
transferred to a 96-well plate, and caffeine concentration was measured by
high-performance liquid chromatography–MS/MS from the calibration curve
using the same conditions as those described for tacrine.
Pharmacokinetic parameters were calculated using Phoenix WinNonlin
version 6.4 (Certara, St. Louis, MO).
Full details of the data analysis are given in the Supplemental Materials.
Results
Generation of hCYP1A1/1A2 and Cyp1a KO Mice.
Homozygous hCYP1A1/1A2 and Cyp1a KO mice appeared normal,
could not be distinguished from WT animals, and had normal survival
rates. There were onlyminor differences between the different lines with
or without TCDD treatment, as shown in Supplemental Table 1.
Total Cytochrome P450.
Total hepatic cytochrome P450 content in untreated WT, hCYP1A1/
1A2, and Cyp1a KO mice was similar, suggesting that Cyp1a1 and
Cyp1a2 are only minor constitutive P450 forms (Fig. 1). Administration
of TCDD resulted in a significant increase of total hepatic cytochrome
P450 in WT mice (2.37-fold, from 355 to 840 pmol/mg protein) and
hCYP1A1/1A2 (1.84-fold, from 344 to 632 pmol/mg protein). As there
was no change in total P450 in Cyp1a KO on TCDD treatment, the
increase was attributable to the induction of CYP1A enzymes inWT and
hCYP1A1/1A2 mice, which accounted for 58% and 46% of the total
hepatic P450 content, respectively.
CYP1A1 and CYP1A2 Protein Expression and Activity.
Western blot analysis showed that CYP1A1 was not expressed
constitutively in the humanized mouse liver but CYP1A2 was (Fig. 2, A
Fig. 6. EROD and MROD activities measured in the presence or absence of quinidine in liver microsomes from TCDD-treated hCYP1A1/1A2 humanized mice. EROD (A)
and MROD (B) with and without quinidine catalyzed by liver microsomes from TCDD-treated hCYP1A1/1A2 humanized mice. Symbols are the measured reaction rates.
Lines are nonlinear regression analysis of the data using eqs. 7 and 8, respectively (for details, see Data Analysis in the Supplemental Materials). Contribution of CYP1A1,
CYP1A2, and non-CYP1A components of the reactions were calculated using eqs. 9–14 (for details, see Data Analysis in the Supplemental Materials) for EROD (C and E)
and MROD (D and F) with (E and F) and without (C and D) quinidine (200 mM).
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and B). Neither protein was expressed constitutively in any other tissue.
Bands observed in vehicle control samples in Fig. 2A and visible in
Cyp1a KO microsomes in Fig. 2D are likely due to nonspecific binding
of CYP1A1 antibodies. On TCDD treatment, both CYP1A1 and
CYP1A2 were induced in the liver and, in the case of CYP1A1, in the
lung and duodenum, with a low level of induction in the ileum and
jejunum. The induction appeared to be less than that for Cyp1a1 in WT
animals (Fig. 2C), but this may relate to the antibodies used. As
expected, both Cyp1a1 and Cyp1a2 (data not shown) could not be
detected in the KO animals irrespective of TCDD treatment.
EROD activity in liver microsomes from Cyp1a KO mice was
decreased by 22% relative toWT animals, while the constitutive activity
was slightly increased (to 155%) in hCYP1A1/1A2 mice (Fig. 3A).
Treatment with TCDD resulted in a marked (;114-fold) increase in
EROD activity in WT and 39-fold in hCYP1A1/1A2 mice relative to
untreated animals. A 3-fold increase in Cyp1a KO liver was also
observed. MROD was decreased by approximately 90% in liver
microsomes from Cyp1a KOmice compared withWT animals, whereas
in the hCYP1A1/1A2 mouse line the activity was unchanged (Fig. 3B).
On TCDD treatment of WT and hCYP1A1/1A2 mice, 44- and 31-fold
increases in MROD activities were measured, respectively. A small
increase in activity (4.6-fold) was also measured in the Cyp1a KO line.
Both EROD andMROD activities were below the limit of detection in
all extrahepatic tissues in all mouse models. On TCDD treatment, these
activities were induced in several tissues of both WT and hCYP1A1/
1A2 mice. The highest activity for both substrates was in the lungs, with
significant activity in the duodenum and other regions of the gastroin-
testinal tract. These data are consistent with the Western blot analysis of
CYP1A1 expression (Fig. 3, A and C). Interestingly, the humanized
samples exhibited higher activities thanWT samples for these substrates.
Estimation of the Relative Contribution of CYP1A2 to EROD and
MROD Activities.
Quinidine is a known inhibitor of the human P450 enzymes CYP2D6
and CYP1A1 but not CYP1A2 (Ching et al., 2001). As CYP2D6 is not
involved to any significant extent in either EROD (McGinnity et al.,
1999) or MROD (Burke et al., 1994), quinidine was used as a CYP1A1-
specific inhibitor in this study. Consistent with the literature (Ching
et al., 2001), recombinant CYP1A1–mediated MROD was strongly
inhibited by quinidine (Fig. 4, IC50 5 5.8 mM), with CYP1A2 having
a much lower affinity (1977 mM). We used this difference to determine
the relative contribution of CYP1A1, CYP1A2, and cytochrome P450s
other than CYP1A to ER and MR metabolism in liver microsomes from
TCDD-treated hCYP1A1/1A2 mice. The overall rate of EROD or
MROD was assumed to be the addition of rates from the CYP1A1,
CYP1A2, and non-Cyp1a components. Initially, the interaction of
substrate and quinidine with each one of the aforementioned compo-
nents was studied individually using human recombinant CYP1A1,
CYP1A2, and microsomes from TCDD-treated Cyp1a KO mice. For
human CYP1A1, EROD and MROD inhibition by quinidine was
consistent with a mixed and competitive mechanism, respectively
(Fig. 5, A and B; Supplemental Scheme 1, a and d, eqs. 1 and 4;
Table 1). Quinidine did not inhibit either EROD or MROD activity
catalyzed by CYP1A2 (Fig. 5, C and D; Supplemental Scheme 1, b and
e, eqs. 2 and 5; Table 1). In TCDD-treated Cyp1a KO samples, both
EROD andMRODwere inhibited noncompetitively with high Ki values
(.200mM) (Fig. 5, E and F; Supplemental Scheme 1, c and f, eqs. 3 and
6; Table 1). Substrate and quinidine binding constants were calculated
for all of the reactionsmeasured earlier (Table 1) and used in eqs. 7 and 8
to relate EROD and MROD reaction rates to concentrations of substrate
and quinidine. It was assumed that the substrate and quinidine binding
affinities of recombinant CYP1A1 and CYP1A2 are the same as those of
CYP1A1 and CYP1A2 in liver microsomes from TCDD-treated
hCYP1A1/1A2 mice. Also, it was assumed that the non-Cyp1a
component of both EROD and MROD in hCYP1A1/1A2 mice
corresponds to the total EROD and MROD in Cyp1a KO mice. Vmax
values for EROD and MROD of the non-Cyp1a component were those
calculated from experiments using liver microsomes from TCDD-
treated Cyp1a KO mice. As a result, eqs. 7 and 8 are left with two
independent variables—namely, substrate and quinidine concentrations
—and two parameters (Vmax for CYP1A1 and CYP1A2). These Vmax
values were calculated by nonlinear regression analysis of reaction rates
in microsomes from TCDD-treated hCYP1A1/1A2 mice at different
concentrations of quinidine and ER (Fig. 6A) orMR (Fig. 6B) using eqs.
7 and 8, respectively. The Vmax values for CYP1A1 and CYP1A2 were
2800 and 1900 pmol/min/mg protein for EROD, and 1600 and 2000
pmol/min/mg protein for MROD, respectively.
With these Vmax values, all parameters in eqs. 7 and 8 became known,
which allowed simulation of the reaction rates in liver microsomes from
hCYP1A1/1A2 mice for any given substrate and quinidine concentra-
tion not only for the general reaction but also for the individual CYP1A1,
CYP1A2, and non-Cyp1a contributions. Using these equations, the
contribution of each individual enzymatic component in liver micro-
somes from TCDD-treated hCYP1A1/1A2 mice for EROD
(Supplemental eqs. 9–11; Fig. 6E) and MROD (eqs. 12–14; Fig. 6, D
and F) was calculated. In the absence of quinidine, the CYP1A1
Fig. 7. EROD and MROD activities catalyzed by liver microsomes from vehicle-treated hCYP1A1/1A2 humanized mice in the presence or absence of quinidine. EROD (A)
and MROD (B) with and without quinidine catalyzed by liver microsomes from vehicle-treated (corn oil) hCYP1A1/1A2 humanized mice. Symbols are the measured
reaction rates, and the line is derived from nonlinear regression analysis of the MROD in the absence of quinidine using eq. 5 (for details see Data Analysis in the
Supplemental Materials).
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contribution to EROD at a low (10 pM) substrate concentration was
calculated to be;94% (Fig. 6C). This decreased to 70% at 1mMER and
further reduced to ;51% at 6 mM substrate. Correspondingly, the
contribution of CYP1A2 was increased from ;4.8% at low substrate
concentration to;45% at 6mMER. The non-Cyp1a contributionwas in
the range of 0.8%–3.9%. At a quinidine concentration of 200 mM and
low concentration of ER, the CYP1A1, CYP1A2, and non-CYP1A
contributions were ;22%, 70%, and 8%, respectively, and did not
change substantially with rise of ER concentration.
CYP1A1 and CYP1A2 contributions to MROD activity were almost
equal (49% and 50%, respectively) at low substrate concentrations in the
absence of inhibitor (Fig. 6D). As MR concentration increased, the
CYP1A1 contribution decreased and CYP1A2 contribution increased,
being ;18% and ;81%, respectively, at 6 mM MR. At low concen-
trations of MR and 200 mM quinidine, the reaction was almost
exclusively catalyzed by CYP1A2 (;98% contribution) with the CYP1A1
impact being less than 1% (Fig. 6F). As the substrate concentration
increased, CYP1A2 contribution decreased to ;90% and CYP1A1
increased to ;9%. Non-Cyp1a contribution to MROD did not exceed
1.5%. In liver microsomes from vehicle-treated hCYP1A1/1A2 mice,
200 mM quinidine resulted in minor inhibition of the EROD, which was
highest (;20%) at high substrate concentrations (Fig. 7A).MRODwas not
affected by the inhibitor (Fig. 7B).
Human recombinant CYP1A1 and CYP1A2 reconstituted from
purified enzymes have been reported to have EROD/MROD activity
ratios of 6.5 and 0.4, respectively, at 10 mM substrate (Liu et al., 2004).
The EROD/MROD ratio for CYP1A1 in hCYP1A1/1A2 liver micro-
somes was calculated by eqs. 1 and 4 using the following assumptions:
1) 10mMsubstrate concentration; 2) absence of inhibitor; 3) substitution
of the substrate binding parameters with corresponding calculated values
from Table 1; and 4) substitution of Vmax parameters for 2800 and 1600
pmol/min/mg protein for EROD and MROD, respectively. The
calculated EROD/MRODactivity ratio using this approachwas8.1 times
for CYP1A1, in good agreement with the published data. The same ratio
for CYP1A2 calculated by eqs. 2 and 5 and using Vmax values of 1909
and 1969 pmol/min/mg protein for EROD and MROD, respectively,
resulted in an activity ratio of 1.64, suggesting a decreased CYP1A2
preference for MROD in mouse liver microsomes compared with the
reconstituted recombinant enzyme system. It should be noted that at
0.5 mM MR, the calculated EROD/MROD activity ratio was 0.63,
suggesting a higher CYP1A2 preference for MROD at low substrate
concentrations. However, at high substrate concentrations, the ratio
changed, possibly due to substrate inhibition.
Fig. 8. Microsomal stability and in vitro clearance of ramelteon and tacrine. Microsomal stability (A and B) and in vitro clearance (C and D) of human CYP1A2 substrates
ramelteon (A and C) and tacrine (B and D) measured in liver microsomes from WT, Cyp1a KO, and hCYP1A1/1A2 mice and human donors (human liver microsomes).
Symbols are the measured concentrations of the compounds. A no-NADPH control was also run. Lines are nonlinear regression analysis using the equation for double-
exponential (tacrine with Cyp1a KO microsomes) or monoexponential (all other incubations) decay in the software package GraFit 7.0.3. (Erithacus, West Sussex, UK).
Fig. 9. Caffeine pharmacokinetics in WT, Cyp1a KO, hCYP1A1/1A2, and HRN
mice. Symbols are caffeine concentrations measured in mouse whole blood. All data
are expressed as the mean 6 S.D. (n 5 4 mice per treatment group).
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Microsomal Stability of Ramelteon and Tacrine.
The CYP1A2-specific substrate ramelteon exhibited monoexponen-
tial decay on incubation with liver microsomes from all vehicle-treated
samples and human liver microsomes (Fig. 8A). Ramelteon in vitro
clearance in Cyp1a KO and hCYP1A1/1A2 mice and pooled human
liver microsomes was ;83%, ;190%, and ;70% relative to WT
animals (Fig. 8C). The values of the fraction metabolized by Cyp1a2/
CYP1A2 were calculated to be;0.17 and 0.56 for WT and hCYP1A1/
1A2 mice, respectively (eqs. 15 and 16). Tacrine depletion was
monoexponential in all samples except Cyp1a KO microsomes, in
which it was preferentially described by the double-exponential decay
equation (Fig. 8B). The in vitro clearance of tacrine in pooled human
liver microsomes was only ;12% of that in WT mice, and in
microsomes from Cyp1a KO and hCYP1A1/1A2 mice it was
;32% and 81% of that in WT animals, respectively (Fig. 8D). The
calculated Cyp1a2/CYP1A2 fraction metabolized values were ;0.68
and ;0.60 for WT and hCYP1A1/1A2 mice, respectively (eqs. 15
and 16).
Caffeine Pharmacokinetics.
Caffeine is a CYP1A2-specific substrate recommended by the Food
and Drug Administration as a sensitive “substrate drug” for in vivo
CYP1A2 drug-drug interaction studies. We therefore studied caffeine
pharmacokinetics in hCYP1A1/1A2 and Cyp1a KO mice. The pharma-
cokinetics of caffeine had similar absorption phases in all mouse lines
(Fig. 9). There was a small increase (,1.7-fold) in the maximum
observed concentration and a minor (,21%) decrease in the apparent
volume of distribution in Cyp1a KO, hCYP1A1/1A2, and HRN mice
compared with theWT animals (Fig. 9; Table 2). In HRN and Cyp1aKO
mice, the elimination half-life was significantly increased (;8.9- and
;2.5-fold, respectively) compared with that measured in the WT. In
hCYP1A1/1A2 mice, the increase was small (;1.4-fold) and not
statistically significant. The area under the curve (AUC) values were
significantly increased (;10-,;3.1-, and;1.5-fold compared withWT
mice), and apparent clearance values were significantly decreased (to
;10%, 32%, and 68% of that in WT mice) in HRN, Cyp1a KO, and
hCYP1A1/1A2 mice, respectively.
Caffeine pharmacokinetics in hCYP1A1/1A2, Cyp1a KO, and HRN
mice were extrapolated to those in humans by a complex Dedrick plot
approach using body weight, clearance, and volume of distribution
values in human obtained from Culm-Merdek et al. (2005) and
hCYP1A1/1A2 mice to calculate parameters of exponential functions
relating clearance and volume of distribution to body weight (Fig. 10;
see Supplemental Materials). The data extrapolated from the different
mouse lines were compared with caffeine pharmacokinetics observed in
healthy human subjects who received placebo or fluvoxamine, a strong
CYP1A2 inhibitor (Culm-Merdek et al., 2005). The extrapolated
caffeine pharmacokinetics in hCYP1A1/1A2 mice were superimposed
with that in humans receiving a placebo, while the extrapolated trace
from HRN mice was close to that measured in human subjects after
coadministration of caffeine and fluvoxamine. Caffeine pharmacokinet-
ics extrapolated from Cyp1a KO mice demonstrated slower elimination
than that in humans with placebo but faster comparedwith that in healthy
subjects after coadministration of fluvoxamine.
Discussion
We have generated and validated two new mouse models, one where
the Cyp1a gene cluster has been deleted and one humanized for
CYP1A1 and CYP1A2. These models have been used to develop
a novel approach to establish the relative roles of CYP1A1 and CYP1A2
in drug disposition. Both CYP1A1 and CYP1A2 are induced as
a consequence of the activation of the Ah receptor, and their overlapping
substrate specificities have led to considerable interest in developing
methods to distinguish their relative contribution to drug oxidation
in vitro and in vivo. One approach has been to use selective CYP1A2
inhibitors, such as fluvoxamine/isosafrole (Pastrakuljic et al., 1997; Sy
et al., 2001) or furafylline (Stiborova et al., 2002, 2005). Recombinant
CYP1A1 and CYP1A2 were used to establish the ratio of activities with
isosafrole or fluvoxamine to that without the inhibitor at a single
substrate and a number of inhibitor concentrations (Pastrakuljic et al.,
1997). Thus, for each inhibitor concentration, there was one ratio for
CYP1A1 and one ratio for CYP1A2. The activity in a sample of human
liver microsomes was measured with and without the inhibitor, and an
TABLE 2
Caffeine pharmacokinetic parameters in hCYP1A1/1A2, Cyp1a KO, WT, and HRN mice Data are the mean 6 S.D. (% mean of C57BL/6J 6 %S.D.); n 5 4.
Mouse Line Cmax V/F(obs) HL AUCinf(obs) CL/F(obs)
ng/ml ml/kg h h*ng/ml ml/h/kg
C57BL/6J 2383 6 628 (100 6 26) 1253 6 494 (100 6 39) 0.94 6 0.25 (100 6 27) 5704 6 1265 (100 6 22) 905 6 170 (100 6 19)
Cyp1a KO 3991 6 472** (167 6 20) 992 6 188 (79 6 15) 2.39 6 0.2*** (253 6 22) 17651 6 2073**** (309 6 36) 286 6 35*** (32 6 4)
hCYP1A1/
1A2
3082 6 194 (129 6 8) 1111 6 55 (89 6 4) 1.3 6 0.33 (138 6 35) 8397 6 1797* (147 6 32) 615 6 121* (68 6 13)
HRN 3744 6 794* (157 6 33) 1057 6 82 (84 6 7) 8.4 6 0.8**** (891 6 85) 57,271 6 2583**** (1004 6 45) 87 6 3.8**** (9.7 6 0.42)
AUCinf(obs), area under the curve from dosing time extrapolated to infinity from the last observed caffeine concentration; CL/F(obs), clearance calculated using AUCinf(obs); Cmax, maximum
observed concentration; HL, terminal half-life; V/F(obs), volume of distribution calculated using AUCinf(obs).
*Significantly different from C57BL/6J (unpaired t test; two-tailed P values; *P , 0.05; **P , 0.01; ***P , 0.001; ****P , 0.0001).
Fig. 10. Caffeine pharmacokinetics in hCYP1A1/1A2, Cyp1a KO, and HRN mice
extrapolated to humans. Caffeine pharmacokinetics in hCYP1A1/1A2, Cyp1a KO,
and HRN mice extrapolated to humans using the complex Dedrick plot approach
(see Materials and Methods for details). The caffeine concentration time course in
placebo- or fluvoxamine-treated healthy subjects (Culm-Merdek et al., 2005) was
corrected for mean caffeine concentration in predose. Symbols are the corrected
caffeine concentrations measured in human plasma or extrapolated from mouse
whole blood. All data are expressed as mean values (n 5 4 mice per treatment
group; n 5 7 healthy subjects per treatment group).
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equation relating the activities measured in human liver microsomes to
the activity ratios in the recombinant enzymes was used to calculate the
individual contribution of CYP1A1 and CYP1A2. However, themethod
has the shortcoming that it uses a single substrate concentration and
a limited number of inhibitor concentrations and thus does not use the
full magnitude of the kinetic data collected. The latter method (Stiborova
et al., 2002, 2005) relies on subtracting activity measured in the presence
of furafylline from that without the inhibitor and relating the difference
to CYP1A1 concentration measured in human liver microsomes by
Western blotting. While the method worked for compounds rapidly
metabolized by CYP1A1, e.g., Sudan I, in the case of EROD the
approach did not work. Incomplete inhibition of CYP1A2 and
contribution from other cytochrome P450s participating in EROD in
the presence of furafylline were considered as possible explanations
(Stiborova et al., 2005).
The present study exploits the Cyp1a KO model together with
quinidine as a specific CYP1A1 inhibitor to define the relative role of
CYP1A1/1A2 in drug metabolism, using EROD and MROD as
exemplar substrates. Our approach involved the derivation of equations
to describe the relationship between reaction rate and substrate and
inhibitor concentrations in liver microsomes from hCYP1A1/1A2 mice.
This mechanistic approach allows modeling of the CYP1A1, CYP1A2,
and non-CYP1A contribution to metabolism of any substrate, at any
substrate, inhibitor, or enzyme concentration, and thus can be easily
integrated into a PBPK model. Through the use of quinidine as
a CYP1A1-specific inhibitor, the CYP1A1 contribution to metabolism
of compounds with a slow reaction rate or where CYP1A1 expression is
low can be determined.
Hepatic CYP1A1 expression in humans has been reported to be
undetectable (McManus et al., 1990; Murray et al., 1993; Edwards et al.,
1998, 2003), while others have quantified the enzyme (Drahushuk et al.,
1998; Stiborova et al., 2005). The individual contribution of CYP1A1
and CYP1A2 to EROD in a panel of human microsomes has been
estimated by selective inhibition of CYP1A2 and CYP1A1 (Pastrakuljic
et al., 1997; Sy et al., 2001). In all human samples, the CYP1A1 content
was either very low, estimated to be ,0.7% of the total hepatic
cytochrome P450 (Stiborova et al., 2005), or below the limit of
detection, inferring that hepatic CYP1A1 is induced rather than
constitutive (Sy et al., 2001). However, due to the very high activity
of CYP1A1 toward some compounds (Roberts-Thomson et al., 1993;
Kreth et al., 2000; Stiborova et al., 2005, 2015; Li et al., 2007; Lin et al.,
2017; MacLeod et al., 2018), it can make a significant contribution to
their metabolism even at very low expression levels—for example,
aristolochic acid (Stiborova et al., 2015), Sudan I (Stiborova et al.,
2005), benzo[a]pyrene (Sulc et al., 2016), granisetron (Nakamura et al.,
2005), riociguat (Khaybullina et al., 2014), and erlotinib (Hamilton et al.,
2006).
While the measured concentration of CYP1A1 in human liver
microsomes is very low [#3 pmol/mg microsomal protein (Stiborova
et al., 2005)], it is inducible in cultured human hepatocytes (Curi-
Pedrosa et al., 1994; Liu et al., 2001) and in human liver slices, where an
expression level of 25–50 pmol/mg microsomal protein was measured
following incubation with TCDD (Drahushuk et al., 1998). The
combination of high activity and inducibility makes CYP1A1 a poten-
tially important contributor to variability in toxico/pharmacokinetics of
environmental toxicants and/or approved drugs. Indeed, the enzyme can
be induced not only by environmental agents but also by prescribed
drugs, such as omeprazole, lansoprazole, albendazole, and primaquine
Fig. 11. Effect of fraction metabolized on AUC ratios of “substrate drug.”
Simulation of AUC ratios of a substrate drug with inhibitor to that without inhibitor
as a function of inhibitor concentration for different contributions of the inhibited
enzyme [fraction metabolized (fm)] to the substrate drug elimination. The enzyme
contribution is expressed as part of total clearance. Horizontal lines separate areas
with strong (AUC ratio .5-fold), moderate (2 , AUC ratio , 5), weak (1.25 ,
AUC ratio , 2), and “no effect” (AUC ratio ,1.25-fold) inhibition.
TABLE 3
Contribution of CYP1A2 to caffeine systemic clearance calculated from published mouse studies The difference between caffeine systemic
clearance in the defined mouse strain and that in the Cyp1a KO mouse line was divided by the value of the systemic clearance in the defined
mouse strain and then multiplied by 100% to obtain the contribution of CYP1A2. The clearance value measured in CYP1A22/2 mice was used
to calculate CYP1A2 contribution to caffeine systemic clearance in C57BL/6N mice reported by Buters et al. (1996).
Mouse Line Dose Route Clearance Reference CYP1A2 Contribution
mg/kg ml/(h*kg) %
CYP1A22/2 2 i.p. 276 Buters et al., 1996 0
C57BL/6N 2 i.p. 2268 Buters et al., 1996 88
Cyp1a KO 5 PO 286 This study 0
C57BL/6J 5 PO 905 This study 68
hCYP1A1/1A2 5 PO 614 This study 53
C57BL/6J 5 PO 472a Li et al., 2017 39
Swiss 20 PO 311b Samojlik et al., 2016 8
Swiss 20 i.p. 398b Samojlik et al., 2016 28
C57BL/6J 5 PO 726 Scheer et al., 2014 61
CD-COBS 1 i.v. 732 Walton et al., 2001 61
CD-1 20 i.p. 640 Kaplan et al., 1990 55
CD-1 40 i.p. 380 Kaplan et al., 1990 25
PO, per os (oral gavage).
aAs it was not clear if the AUC reported in the paper was an AUCinf, caffeine clearance was calculated from the C57BL/6J mean pharmacokinetic profile presented
in Fig. 2 in the publication (Li et al., 2017).
bClearance was calculated by dividing dose by AUCinf.
916 Kapelyukh et al.
 at A








(Curi-Pedrosa et al., 1994; Krusekopf et al., 2003; Ueda et al., 2006;
Thorn et al., 2012).
In this study, recombinant CYP1A1 metabolized ER with a Vmax of
3300 pmol/min/mg protein at an enzyme concentration of 71 pmol/mg
protein, giving a kcat of 47 minutes
21. The concentration of hepatic
CYP1A1 in TCDD-treated hCYP1A1/1A2 mice, estimated from the
ratio of CYP1A1 EROD Vmax (2800 pmol/min/mg protein) to kcat
(47 minutes21), is 59 pmol/mgmicrosomal protein. This is in reasonable
agreement with the CYP1A1 concentration range of 25–50 pmol/min/
mg microsomal protein, obtained in human liver slices incubated with
TCDD (Drahushuk et al., 1998), suggesting that any variability in
CYP1A1 activity due to induction can be modeled in hCYP1A1/1A2
mice, and its relation to variability in pharmacokinetics of any given
drug can be modeled and tested.
CYP1A2 in untreated humanized mice had a much higher activity
than Cyp1a2 in the oxidation of ramelteon. Indeed, the contribution of
mouse Cyp1a2 to clearance of this substrate was only 17%, whereas in
the liver microsomes of hCYP1A1/1A2 mice it was increased to 56%,
close to that observed in human liver microsomes in vitro (Obach and
Ryder, 2010). Similarly, CYP1A2 exhibited a higher EROD activity
than Cyp1a2. The MROD efficacy of both enzymes was similar,
whereas tacrine oxidation was faster in liver microsomes from C57BL/
6J mice compared with that in the humanized animals. These
observations highlight and substantiate the reported species differences
in the metabolism of various CYP1A2/Cyp1a2 substrates (Turesky
et al., 1998).
The contributions of Cyp1a2 and CYP1A2 to caffeine clearance in
WT or hCYP1A1/1A2 were 68% and 53%, respectively (Table 3),
suggesting that themouse enzyme plays a slightly greater role in caffeine
disposition. The Cyp1a2 contribution was lower than the 87% estab-
lished using a Cyp1a2 knockout model (Buters et al., 1996). However,
as shown in Table 3, the clearance values for the WT mice in the Buters
study were abnormally high, and the clearance measured in the Cyp1a
KO mice was the same. In this study, we demonstrated the power of
using the Cyp1aKO in conjunction with the humanizedmouse to clearly
establish the contribution of a particular enzyme in drug elimination.
This is important in the study of drug-drug interactions (Fig. 11). At an
inhibitor concentration of 10 times Ki, where the contribution of the
enzyme to elimination is 87%, the “substrate drug” AUC will increase
approximately 5-fold. This would be considered a strong drug-drug
interaction. However, with a 68% enzyme contribution to the drug
clearance, the AUC will only increase approximately 2.5-fold, corre-
sponding to a moderate interaction. For a 53% enzyme contribution, the
AUC increase will be less than 2-fold and will have a weak effect. The
interaction of caffeine with fluvoxamine, a strong CYP1A2 inhibitor,
suggested a 93% contribution of CYP1A2 to caffeine metabolism in
healthy subjects (Culm-Merdek et al., 2005).
When caffeine pharmacokinetics in hCYP1A1/1A2 mice were
extrapolated to humans, as described in the Materials and Methods,
the pharmacokinetic curves were almost identical (Fig. 10). In the case of
Cyp1a KO mice, which have no hepatic CYP1A2 activity and are
therefore comparable to humans when CYP1A2 is completely inhibited,
the extrapolated curve from the null mice suggested notably faster
caffeine elimination than that observed in individuals coadministered
with the CYP1A2 inhibitor fluvoxamine. However, caffeine elimination
extrapolated fromHRNmice was superimposablewith the fluvoxamine-
treated group, suggesting the involvement of P450s other than Cyp1a2
in metabolism. Although this could be considered a confounding factor
in the use of the model, it also demonstrates how the model can identify
other enzymes involved in drug disposition. A contribution of the
murine enzymes to the fraction metabolized is likely to be reduced using
the more complex humanized model we have reported recently. In this
model, 32 murine P450s from four gene subfamilies have been deleted
and substituted for the major human P450s involved in foreign
compound metabolism, along with constitutive androstane receptor
and pregnane X receptor, themajor transcription factors involved in their
regulation (Henderson et al., 2019).
The mechanistic approach developed in this study was successfully
applied to calculate the individual contribution of human CYP1A1 and
CYP1A2 to the metabolism of model compounds ER and MR in liver
microsomes from TCDD-treated hCYP1A1/1A2 mice. When applied to
a new chemical entity, the method will provide data for the development
of a PBPK model, and the predicted interplay between compound
concentration and expression of CYP1A1 and CYP1A2 can be tested
in vivo using hCYP1A1/1A2 and Cyp1a KO mice. This represents
a significant improvement of the currently used in vitro approaches, as it
allows the validity of models to be tested in vivo. Humanization for
CYP1A1 and CYP1A2, and particularly the use of complex humanized
models such as that reported recently (Henderson et al., 2019), will
improve the accuracy of extrapolation of preclinical data to humans.
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